FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095309637> ?p ?o ?g. }

• W2095309637 endingPage "H1276" @default.
• W2095309637 startingPage "H1267" @default.
• W2095309637 abstract "The importance of chronic stimulation of β-adrenoceptors in the development of cardiac dysfunction is the rationale for the use of β-blockers in the treatment of heart failure. Nebivolol is a third-generation β-blocker, which has further properties including stimulation of endothelial nitric oxide synthase and/or β 3 -adrenoceptors. The aim of this study was to investigate whether nebivolol has additional effects on β-adrenoceptor-mediated functional responses along with morphologic and molecular determinants of cardiac hypertrophy compared with those of metoprolol, a selective β 1 -adrenoceptor blocker. Rats infused by isoprenaline (100 μg·kg −1 ·day −1 , 14 days) were randomized into three groups according to the treatment with metoprolol (30 mg·kg −1 ·day −1 ), nebivolol (10 mg·kg −1 ·day −1 ), or placebo for 13 days starting on day 1 after implantation of minipump. Both metoprolol and nebivolol caused a similar reduction on heart rate. Nebivolol mediated a significant improvement on cardiac mass, coronary flow, mRNA expression levels of sarcoplasmic reticulum Ca 2+ ATPase (SERCA2a) and atrial natriuretic peptide and phospholamban (PLN)/SERCA2a and phospho-PLN/PLN ratio compared with metoprolol and placebo. Nebivolol prevented the detrimental effects of isoprenaline infusion on isoprenaline (68% of control at 30 μM), BRL37344 (63% of control at 0.1 μM), and forskolin (64% of control at 1 μM) responses compared with metoprolol (isoprenaline, 34% of control; BRL37344, no response; forskolin, 26% of control) and placebo (isoprenaline, 33% of control; BRL37344, 28% of control; forskolin, 12% of control). Both β-blockers improved the changes in mRNA expressions of β 1 - and β 3 -adrenoceptors. Our results suggest that nebivolol partially protects the responsiveness of β-adrenoceptor signaling and the development of cardiac hypertrophy independent of its β 1 -adrenoceptor blocking effect." @default.
• W2095309637 created "2016-06-24" @default.
• W2095309637 creator A5003485916 @default.
• W2095309637 creator A5014931781 @default.
• W2095309637 creator A5025585835 @default.
• W2095309637 creator A5032263710 @default.
• W2095309637 creator A5039653538 @default.
• W2095309637 creator A5073029082 @default.
• W2095309637 creator A5075802434 @default.
• W2095309637 date "2013-05-01" @default.
• W2095309637 modified "2023-10-18" @default.
• W2095309637 title "Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β₁-adrenoceptor blockage" @default.
• W2095309637 cites W1518281645 @default.
• W2095309637 cites W1742928928 @default.
• W2095309637 cites W1963616721 @default.
• W2095309637 cites W1983692570 @default.
• W2095309637 cites W1984401650 @default.
• W2095309637 cites W1991620824 @default.
• W2095309637 cites W2001261561 @default.
• W2095309637 cites W2009566289 @default.
• W2095309637 cites W2025335579 @default.
• W2095309637 cites W2028761750 @default.
• W2095309637 cites W2029609182 @default.
• W2095309637 cites W2037065101 @default.
• W2095309637 cites W2058134019 @default.
• W2095309637 cites W2064192933 @default.
• W2095309637 cites W2066825816 @default.
• W2095309637 cites W2072432861 @default.
• W2095309637 cites W2081169322 @default.
• W2095309637 cites W2091583229 @default.
• W2095309637 cites W2095221846 @default.
• W2095309637 cites W2097158209 @default.
• W2095309637 cites W2098842290 @default.
• W2095309637 cites W2107554716 @default.
• W2095309637 cites W2108244474 @default.
• W2095309637 cites W2117156482 @default.
• W2095309637 cites W2138354938 @default.
• W2095309637 cites W2138377901 @default.
• W2095309637 cites W2150148660 @default.
• W2095309637 cites W2152907499 @default.
• W2095309637 cites W2158714558 @default.
• W2095309637 cites W2158757718 @default.
• W2095309637 cites W2158800467 @default.
• W2095309637 cites W2159981314 @default.
• W2095309637 cites W2166068071 @default.
• W2095309637 cites W2166383881 @default.
• W2095309637 cites W2167333537 @default.
• W2095309637 cites W2167760816 @default.
• W2095309637 cites W2195870368 @default.
• W2095309637 cites W2916505054 @default.
• W2095309637 cites W4229759864 @default.
• W2095309637 doi "https://doi.org/10.1152/ajpheart.00352.2012" @default.
• W2095309637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23457011" @default.
• W2095309637 hasPublicationYear "2013" @default.
• W2095309637 type Work @default.
• W2095309637 sameAs 2095309637 @default.
• W2095309637 citedByCount "16" @default.
• W2095309637 countsByYear W20953096372014 @default.
• W2095309637 countsByYear W20953096372015 @default.
• W2095309637 countsByYear W20953096372016 @default.
• W2095309637 countsByYear W20953096372018 @default.
• W2095309637 countsByYear W20953096372019 @default.
• W2095309637 countsByYear W20953096372020 @default.
• W2095309637 countsByYear W20953096372021 @default.
• W2095309637 countsByYear W20953096372022 @default.
• W2095309637 crossrefType "journal-article" @default.
• W2095309637 hasAuthorship W2095309637A5003485916 @default.
• W2095309637 hasAuthorship W2095309637A5014931781 @default.
• W2095309637 hasAuthorship W2095309637A5025585835 @default.
• W2095309637 hasAuthorship W2095309637A5032263710 @default.
• W2095309637 hasAuthorship W2095309637A5039653538 @default.
• W2095309637 hasAuthorship W2095309637A5073029082 @default.
• W2095309637 hasAuthorship W2095309637A5075802434 @default.
• W2095309637 hasConcept C126322002 @default.
• W2095309637 hasConcept C134018914 @default.
• W2095309637 hasConcept C24998067 @default.
• W2095309637 hasConcept C2776090920 @default.
• W2095309637 hasConcept C2776525901 @default.
• W2095309637 hasConcept C2777537511 @default.
• W2095309637 hasConcept C2778151854 @default.
• W2095309637 hasConcept C2778198053 @default.
• W2095309637 hasConcept C2779276759 @default.
• W2095309637 hasConcept C2779670145 @default.
• W2095309637 hasConcept C2781280847 @default.
• W2095309637 hasConcept C71924100 @default.
• W2095309637 hasConcept C84393581 @default.
• W2095309637 hasConceptScore W2095309637C126322002 @default.
• W2095309637 hasConceptScore W2095309637C134018914 @default.
• W2095309637 hasConceptScore W2095309637C24998067 @default.
• W2095309637 hasConceptScore W2095309637C2776090920 @default.
• W2095309637 hasConceptScore W2095309637C2776525901 @default.
• W2095309637 hasConceptScore W2095309637C2777537511 @default.
• W2095309637 hasConceptScore W2095309637C2778151854 @default.
• W2095309637 hasConceptScore W2095309637C2778198053 @default.
• W2095309637 hasConceptScore W2095309637C2779276759 @default.
• W2095309637 hasConceptScore W2095309637C2779670145 @default.
• W2095309637 hasConceptScore W2095309637C2781280847 @default.
• W2095309637 hasConceptScore W2095309637C71924100 @default.

• next